Mylan to cut 100 in Puerto Rico

Workers in Caguas, Puerto Rico, braced for the axe as Mylan announced it would eliminate 100 of the 500 positions at that manufacturing plant. The generics maker announced back in March that it would embark on a big restructuring plan to cut costs, eliminating some jobs in the process, but this the first tangible evidence of that plan in motion. In cutting back on the manufacturing side, Mylan joins a host of other drugmakers, some of which have shuttered entire plants as they streamline operations and outsource more operations. In Puerto Rico alone, pharma has sliced some 3,000 jobs.

- read the Associated Press story
- see the Pharmalot post

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.